With the global launch on August 14th 2020, Shreis Scalene Therapeutics LLC (SSTx) has worked on a path to market for the U.S., and has fast-tracked go-to-market strategies in Latin America, Mexico, Canada, and the Caribbean for the Scalene Hypercharge Corona Canon (SHYCOCAN®).

In the U.S., the SHYCOCAN® was marketed under U.S. FDA Enforcement Discretion until November 2023. Additional product development including clinical validation and collection of real-world evidence is ongoing for this market.

Shreis Scalene Group

Shreis consists of 3 health-tech companies with safe, patient-centric, non-invasive technologies to address a variety of human health issues. It is poised to bring in cutting edge, novel, therapeutic medical devices for cancer, musculoskeletal disorders, degenerative lung conditions, wound healing & insulin dependent diabetes, a device intended to physically attenuate/disable certain viruses, including coronaviruses, and a diagnostic device, for precision cardiovascular disease detection. The region of our focus will be in the North and South American markets, including Mexico and the Caribbean, and in some instances, the Middle East.

The three companies and devices in the Shreis Scalene Group portfolio are;

• Shreis Scalene Sciences LLC - Validated engineering solutions to human health problems

  • Cytotron® - Shreis Scalene Sciences is bringing to market a patented, non- invasive, therapeutic device called the CYTOTRON® delivering Quantum Magnetic Resonance Therapy (QMRT), in the realm of Regenerative Medicine. This tissue engineering platform technology uses safe radio frequencies at the lower end of the electromagnetic (EM) spectrum, lower than cell phones and microwaves, to either regenerate diseased tissue in musculo-skeletal diseases (like Osteoarthritis of any joint, cervical spondylosis, disc prolapse, spinal injuries, low back pain etc.) or destroy tumor proliferation and degenerate cancer tissue.

  • CellFORN® - Facilitating non-invasive cancer drug delivery to improve efficacy and reduce life-threatening cytotoxicity of chemotherapeutic drugs.

    Shreis Scalene Sciences is bringing to market a patent protected, non-invasive, drug delivery technology called Focused Resonance Nano-permeabilization (CELLFORN™), that uses radio-frequencies (RF) and Magnetic Resonance (MR) to selectively target, distribute and deliver chemotherapeutic drug molecules (large and small) or pain medication, within tumor lesions specifically. The concurrent use of FORN with cancer drug delivery mitigates severe systemic toxicities induced by residual drug in circulation. The failure of good drugs in late stages of clinical development due to serious adverse effects, and the ineffective use of chemotherapy as the ‘gold standard’ or for in-effective ‘palliation’ in end-stage disease can be given the much needed impetus. Salvaging beneficial drugs, improving compliance to chemotherapy and driving better outcomes in adult and pediatric patients in the goal for CELLFORN.

• Shreis Scalene Therapeutics LLC

  • SHYCOCAN® - A device intended for the Attenuation/Disabling of coronaviruses* and Influenza B

    Shreis Scalene Therapeutics prioritized R&D for the SHYCOCAN® project intended to deactivate certain viruses including coronaviruses, the virus associated with COVID-19.
    *99.994% ( >4 log10 ) reduction observed in a standard MS2 Bacteriophage decontamination assay; 99.963% reduction of an EPA-approved SARS-CoV-2 surrogate, and elimination of expected Influenza B viral loads, in BSL-2 facilities (Peer-reviewed publication in progress). SARS-CoV-2 assays in BSL-3 facilities are currently underway.

• Shreis Scalene Cardiotech LLC

  • Haemoseis-256 - Non-invasive cardiovascular diagnostic device for comprehensive assessment of an individual’s cardio-pulmonary and renal physiology, with accuracy, ease of use and cost efficiency.

    Shreis Scalene Cardiotech is bringing to market a medical device, Haemoseis-256® - 3 Dimensional Vasculography for Non-Invasive Cardiovascular Diagnostics.

Mission & Vision

• To provide non-invasive, safe, therapeutic & diagnostic health care solutions to enhance quality of life

• To fill unmet medical needs within affordable budgets & insurance cover

• Offer patient-centric healthcare with personalized, precision medicine, individualized for adults and pediatric indications

• Spearhead disruptive technologies that will fill in for expensive diagnostic & therapeutic interventions - beyond the reach of the common man

• Alleviate pain and suffering from debilitating diseases and provide quality and dignity of life, even in end-of-life situations

• Establish collaborations through private-public-large pharma partnerships to facilitate global clinical studies to benefit larger populations

Goals

A Brief History of Shreis

Coming Soon…